ABBV-576 + Galicaftor + Placebo + Navocaftor + ABBV-119
Phase 2Terminated 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Cystic Fibrosis (CF)
Conditions
Cystic Fibrosis (CF)
Trial Timeline
Sep 20, 2021 → Jun 5, 2023
NCT ID
NCT04853368About ABBV-576 + Galicaftor + Placebo + Navocaftor + ABBV-119
ABBV-576 + Galicaftor + Placebo + Navocaftor + ABBV-119 is a phase 2 stage product being developed by AbbVie for Cystic Fibrosis (CF). The current trial status is terminated. This product is registered under clinical trial identifier NCT04853368. Target conditions include Cystic Fibrosis (CF).
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04853368 | Phase 2 | Terminated |
Competing Products
20 competing products in Cystic Fibrosis (CF)